Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | LRAT | O95237 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | GJA1 | P17302 | 1/20 | 0.45 |
| ▸ | GJB2 | P29033 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8886136 | 1.00 | TSHR (0.57) | TSHRHSD17B10LRATMEN1TRPV1 | |
| SCHEMBL14960710 | 1.00 | TSHR (0.57) | TSHRHSD17B10LRATMEN1TRPV1 | |
| SCHEMBL14376646 | 1.00 | TSHR (0.57) | TSHRHSD17B10LRATMEN1TRPV1 | |
| SCHEMBL3681479 | 1.00 | TSHR (0.57) | TSHRHSD17B10LRATMEN1TRPV1 | |
| SCHEMBL24372177 | 1.00 | TSHR (0.57) | TSHRHSD17B10LRATMEN1TRPV1 | |
| SCHEMBL23259481 | 1.00 | TSHR (0.57) | TSHRHSD17B10LRATMEN1TRPV1 | |
| SCHEMBL19090412 | 1.00 | TSHR (0.57) | TSHRHSD17B10LRATMEN1TRPV1 | |
| SCHEMBL425646 | 1.00 | TSHR (0.57) | TSHRHSD17B10LRATMEN1TRPV1 | |
| SCHEMBL21916330 | 1.00 | TSHR (0.57) | TSHRHSD17B10LRATMEN1TRPV1 | |
| SCHEMBL19074569 | 1.00 | TSHR (0.57) | TSHRHSD17B10LRATMEN1TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11780970-B2 | Carbohydrate crosslinker | GALDERMA HOLDING S.A. (CH) | 2023-10-10 | — | — | US | disclosed |
| US-20230212360-A1 | CARBOHYDRATE CROSSLINKER | Galderma Holding SA (CH) | 2023-07-06 | — | — | US | disclosed |
| US-20100323976-A1 | NOVEL ANTI-INFLAMMATORY PRO-DRUGS | ACADEMISCH MEDISCH CENTRUM (NL) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11780970-B2 | Carbohydrate crosslinker | CD44, CSGALNACT1, STT3B | TSHR 1236/4885HSD17B10 1478/4885LRAT 1946/4885 |
| US-20100323976-A1 | NOVEL ANTI-INFLAMMATORY PRO-DRUGS | MSR1, ARG1, CD209 | TSHR 2892/4885HSD17B10 1992/4885LRAT 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.